Seeking Alpha

Coronado Biosciences starts Phase 2 ulcerative colitis study with TSO

  • Coronado Biosciences (CNDO) initiates a Phase 2 study of CNDO-201 in patients with ulcerative colitis.
  • The trial is sponsored by the National Institutes of Health and will "evaluate the [drug's] effect on clinical response of UC, intestinal mucosal immunological response, and inflammatory markers."
  • Primary endpoint is clinical response.
  • This is the third Phase 2 trial for CNDO-201. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|